Abstract:Aim: Colchicine, a microtubule-disassembling (antitubulin) agent used for centuries for the treatment of gout and autoimmune diseases, is a drug of growing interest in the cardiovascular field. While in the last decades it has become cornerstone of pericarditis treatment, it has also emerged in the last few years as a promising drug in the management of coronary artery disease, atrial fibrillation and heart failure. This systematic review and meta-analysis aimed to assess the efficacy of colchicine in patients with cardiovascular diseases. Methods: Systematic search in electronic databases (MEDLINE/PubMed, Scopus, BioMed Central, the Cochrane Collaboration Database of Randomized Trials, ClinicalTrials.gov, EMBASE, Google Scholar) was performed to identify randomized controlled trials (RCTs) up to February 2021. Random-effects meta-analysis was performed to assess the risk of cardiovascular events, defined according to clinical setting. Results: Among 15,569 pooled patients from 21 RCTs, colchicine was superior to placebo in the reduction of cardiovascular events. In the setting of pericardial diseases, it was associated with a lower risk of recurrent pericarditis (17 vs 34%, RR = 0.50, 95% CI: 0.42-0.60, I2 = 10%). In other studies assessing coronary artery disease patients, colchicine was associated with a reduced risk of major adverse cardiovascular events (MACE) such as myocardial infarction, stroke, cardiovascular death, coronary revascularisation and hospitalization (6.3 vs 9%, RR = 0.67, 95% CI: 0.54-0.84, I2 = 55). Among patients with atrial fibrillation, it was associated with lower rates of recurrence (20 vs 30%, RR = 0.68, 95% CI: 0.58-0.81, I2 = 0). In the single RCT on heart failure, colchicine was not associated with improved NYHA class. Conclusion: Colchicine is a valuable anti-inflammatory agent for the prevention of cardiovascular events in patients with inflammatory cardiac conditions such as pericardial diseases, coronary artery disease and atrial fibrillation.

Colchicine in dermatology.

Colchicine Pharmacokinetics and Mechanism of Action.

Colchicine in Renal Medicine: New Virtues of an Ancient Friend

Colchicine's Role in Cardiovascular Disease Management

Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review

Colchicine for the treatment of the spectrum of cardiovascular diseases: current evidence and ongoing perspectives

The Role of Colchicine in Different Clinical Phenotypes of Behcet Disease

Puzzling Out the Colchicine Biosynthetic Pathway

Seeing Colchicine in a New Light: Repurposing Low-dose Colchicine for Secondary Prevention of Cardiovascular Disease

Gloriosa superba, a Source of the Bioactive Alkaloid Colchicine: Chemistry, Biosynthesis and Commercial Production

Colchicine for cardiovascular medicine: a systematic review and meta-analysis

Inhibition of CYP1A1 Alleviates Colchicine-Induced Hepatotoxicity

Colchicine in Athero-Thrombosis: Molecular Mechanisms and Clinical Evidence

Colchicine Increases Intestinal Permeability, Suppresses Inflammatory Responses, and Alters Gut Microbiota in Mice.

Identification of Glycine Receptor Α3 As a Colchicine-Binding Protein.

Colchicine efficacy and safety for the treatment of cardiovascular diseases

Colchicine Increases Intestinal Toxic Load by Disturbing Fecal Metabolome Homeostasis in Mice

Delivery Strategies for Colchicine as a Critical Dose Drug: Reducing Toxicity and Enhancing Efficacy

The Action of Colchicine in Patients with Metabolic Syndrome and Obesity: Perspectives and Challenges

Comprehensive Multi-Omics Analysis Elucidates Colchicine-Induced Toxicity Mechanisms and Unveils the Therapeutic Potential of MLN4924 and Kinase Inhibitors

S3108 Rhabdomyolysis with Diarrhea: A Rare Case of Colchicine Toxicity